ZVRA

$10.26+1.58%

ZEVRA THERAPEUTICS, INC.

Market Cap

$611M

Live price × SEC shares (Oct 30, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.99

60mo monthly vs SPY

P/E (TTM)

8.4

TTM to Sep 2026 · diluted EPS

P/S (TTM)

4.1

TTM to Sep 2026 · revenue

P/B

2.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

4.5

TTM to Sep 2026 · EV incl. net debt

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	34,125	36,220	39,663	37,756	147,764
Research & development	2,620	4,392	4,486	4,937	16,435
Selling, general & administrative	20,354	20,783	16,559	19,130	76,826
Operating income	9,315	52,146	16,777	11,580	89,818
Interest expense	1,948	1,711	0	0	3,659
Pretax income	12,666	44,804	12,794	19,718	89,982
Income tax	501	6,914	4,042	510	11,967
Net income	12,165	37,890	8,752	19,208	78,015
EPS (basic) ($)		0.62	0.14	0.31	1.27
EPS (diluted) ($)		0.60	0.14	0.26	1.22
Weighted avg. shares (basic)		58,406	59,156	59,407
Weighted avg. shares (diluted)		60,230	61,337	61,732

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 3, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 47 more quarters, back to Mar 2014, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Nov 3, 2026 accepted 4:08 PM ET	2.02Earnings release	Document SEC ↗
Aug 5, 2026 accepted 8:13 PM ET	2.02Earnings release	Document SEC ↗
Jun 5, 2026 accepted 8:19 PM ET	5.07Shareholder vote	Document SEC ↗
May 6, 2026 accepted 8:05 PM ET	2.02Earnings release	Document SEC ↗
Mar 16, 2026 accepted 11:31 AM ET	1.01Material agreement1.02Agreement terminated7.01Reg FD disclosure	Document SEC ↗
Mar 9, 2026 accepted 8:06 PM ET	2.02Earnings release5.02Officer / director change	Document SEC ↗
Dec 17, 2025 accepted 9:15 PM ET	5.02Officer / director change	Document SEC ↗
Dec 2, 2025 accepted 12:34 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Nov 20, 2025 accepted 9:29 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Nov 5, 2025 accepted 9:08 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

49%

W/W -24.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

12.95x

Avg Daily Selling (90d)

833 sh/day

Baseline Daily Selling

165 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-12	2026-10-13	McFarlane Neil F.	Director & President and CEO	Sale	20.0K	$11.25	$225K	417.2K	View
2026-08-14	2026-08-17	Thompson Rahsaan	Chief Legal & Compliance	Sale	42.7K	$11.13	$475K	37.6K	View
2026-08-10	2026-08-12	Watton Corey Michael	Director	Sale	12.3K	$11.25	$138K	1,800	View
2026-06-22	2026-06-23	Thompson Rahsaan	Chief Legal & Compliance	Sale	34.6K	$12.68	$438K	80.2K	View
2026-05-11	2026-05-13	Thompson Rahsaan	Chief Legal & Compliance	Sale	1,794	$11.30	$20K	48.1K	View

1–5 of 7

1 / 2

Recent News

Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...

Yahoo Finance Singapore · 2026-11-04

Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript

SeekingAlpha · 2026-11-03

Zevra Therapeutics Q3 Earnings Call Highlights

Yahoo · 2026-11-03

ZVRA: MIPLYFFA-led revenue grew 45%, supporting expansion and pipeline investment

TradingView · 2026-11-03

Zevra Therapeutics Q3 2026 Earnings Call Transcript

Benzinga · 2026-11-03

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates

Yahoo · 2026-11-03

Zevra Therapeutics: Q3 Earnings Snapshot

Yahoo · 2026-11-03

Zevra Reports Third Quarter 2026 Financial Results and Corporate Update

Yahoo · 2026-11-03

symbol__ Stock Quote Price and Forecast

CNN · 2026-11-03

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

Yahoo · 2026-10-20

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

SeekingAlpha · 2026-10-15

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Benzinga · 2026-10-08

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

SeekingAlpha · 2026-10-06

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance · 2026-08-21

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Yahoo Finance · 2026-08-07

Informational purposes only, not investment advice.

ZVRA

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-10-12	McFarlane Neil F.	S	20,000	$224,948
2026-08-14	Thompson Rahsaan	S	42,666	$474,774.45
2026-08-10	Watton Corey Michael	S	12,300	$138,377.46
2026-06-22	Thompson Rahsaan	S	34,557	$438,303.71
2026-05-11	Thompson Rahsaan	S	1,794	$20,272.2